Last updated: February 15, 2026
Overview of the Drug
NDC 43598-0603 corresponds to Fasenra (benralizumab), a monoclonal antibody used for severe eosinophilic asthma, including maintenance treatment of adult patients with this condition. It was approved by the FDA in November 2017. The drug is primarily administered via subcutaneous injection, with dosing typically every four weeks after an initial loading phase.
Market Landscape
The asthma biologic market is competitive with several approved therapies, including:
- Nucala (mepolizumab)
- Cinqair (reslizumab)
- Dupixent (dupilumab)
Fasenra targets the IL-5 receptor alpha, offering a specific mechanism of action for eosinophilic airway inflammation.
Market Size and Demand Drivers
- The global asthma market is approximately $24 billion annually, with biologics representing a growing segment.
- Estimated U.S. severe eosinophilic asthma prevalence is about 2.8 million people.
- Market expansion hinges on increasing diagnosis rates, off-label use, and evolving treatment guidelines favoring biologics.
Competitive Analysis
| Feature |
Fasenra |
Nucala |
Cinqair |
Dupixent |
| Year of Approval |
2017 |
2015 |
2016 |
2017 |
| Efficacy |
Eosinophil reduction |
Eosinophil reduction |
Eosinophil reduction |
IL-4/IL-13 inhibition |
| Dosing Frequency |
Q4 weeks initially, then Q4 weeks |
Q4 weeks |
Q4 weeks |
Q2 weeks (initially), Q2 or Q4 |
| Administration |
Subcutaneous |
Subcutaneous |
IV infusion |
Subcutaneous |
| Key Attributes |
Specific IL-5R alpha targeting |
Similar mechanism |
Similar mechanism |
Broader cytokine targeting |
Pricing Analysis
| Drug |
List Price per Dose |
Approximate Annual Cost |
Notes |
| Fasenra |
$32,500 |
$130,000 (assuming Q4 weeks) |
Based on a 13-dose schedule annually |
| Nucala |
$31,000 |
$124,000 |
Similar schedule to Fasenra |
| Cinqair |
$33,000 |
$132,000 |
IV infusion incurs additional administration costs |
| Dupixent |
$37,500 |
$150,000 |
More frequent dosing (every other week) |
- Variations depend on negotiated insurance and patient assistance programs.
Price Trends and Future Projections
- The average price per dose for biologics in asthma has demonstrated 3-5% annual increases, attributed to inflation, manufacturing costs, and clinical value enhancements.
- Patent protection for Fasenra is expected to extend into 2030, barring any patent litigations or biosimilar approvals.
Potential Price Adjustments
- As biosimilars or generics emerge, prices could decrease by 20-40% over 3-5 years.
- Market access initiatives and value-based pricing may influence final patient costs and reimbursement rates.
Market Penetration and Revenue Forecasts
| Year |
Estimated Market Share |
Projected Revenue (USD) |
Assumptions |
| 2023 |
15% |
$20 million |
Steady growth with increased adoption |
| 2025 |
25% |
$50 million |
Expansion into additional indications |
| 2030 |
35% |
$90 million |
Increased market adoption, biosimilar threat |
Regulatory and Policy Environment
- The FDA permits biosimilar competition, with approved biosimilars for related cytokine therapies emerging.
- Reimbursement policies are increasingly favoring value-based models, influencing pricing strategies.
Summary
NDC 43598-0603 (Fasenra) operates within a competitive biologic asthma market projected to grow at a CAGR of approximately 4% over the next five years. Its current annual list price hovers around $130,000 per patient, with gradual increases expected. Price erosion from biosimilars could impact market share and revenue, especially after patent expirations.
Key Takeaways
- Fasenra commands similar pricing to competitors like Nucala and Cinqair but maintains a slight premium due to its targeted mechanism.
- The market is expected to grow moderately, driven by increased diagnoses and shift toward biologic therapies.
- Biosimilar entry will likely pressure prices downward, with a potential 20-40% cost reduction over the next 5 years.
- Product utilization depends heavily on clinical guidelines, healthcare provider preferences, and payer policies.
- Revenue growth hinges on expanding indications and improving market penetration.
FAQs
1. What factors influence the pricing of Fasenra?
Pricing depends on manufacturing costs, market competition, regulatory environment, and negotiated payer agreements. The FDA’s approval of biosimilars could press prices downward.
2. How does Fasenra's efficacy compare to similar biologics?
Fasenra shows comparable eosinophil reduction efficacy to Nucala and Cinqair. Choice often hinges on dosing schedules, patient convenience, and physician preference.
3. When might biosimilars impact Fasenra's market share?
Biosimilars are expected to enter the U.S. market around 2025-2027, potentially reducing prices and market share for originator biologics.
4. What are the primary revenue risks for Fasenra?
Patent expiration, biosimilar competition, shifts in treatment guidelines, and payer restrictions may reduce revenues.
5. Are there upcoming regulatory changes that could affect the market?
Yes, increased focus on value-based arrangements and accelerated approval pathways for biosimilars may influence market dynamics and pricing strategies.
Sources
- U.S. Food and Drug Administration. Fasenra (benralizumab) approval details. 2017.
- IQVIA. Biologic market analysis reports. 2022.
- Drugs.com. Current list prices for biologics. 2023.
- FDA. Biosimilar guidelines and approvals. 2022.
- MarketWatch. Biologic asthma market forecasts. 2023.
